Oxford BioDynamics builds on US presence
March 9, 2017Oxford BioDynamics has appointed a new Senior Vice President of Commercial Development to be based in the US. The new VP is Martin Reeves, who will take up this role in March 2017.
Reeves has over 20 years’ experience in business development and strategic planning, including Teva Pharmaceuticals where he was Head of Business Development for Global Branded Products. He was previously Vice President of Business Development and Strategic Planning at Cephalon where, in his fourteen years at the company, he played a key role in defining the strategic direction for growth and diversification globally, including planning strategies to enter into new markets such as Asia. Cephalon was bought by Teva in 2011 for $6.8 billion.
Christian Hoyer Millar, CEO of Oxford BioDynamics said Reeves’s experience in business development within the sector will be a great asset to Oxford BioDynamics as the company looks to leverage IP licensing opportunities with its technology platform, EpiSwitch.
